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Abstract 
Cytogenetic aberration and loss of heterozygosity (LOH) are documented on chromosome 6 
in many cancers and the introduction of a neo-tagged chromosome 6 into breast cancer cell 
lines mediates suppression of tumorigenicity. In this study, we described the identification of 
KIAA1949 (phostensin) as a putative tumor suppressor gene. Our microarray analysis 
screened 25,985 cDNAs between a tumorigenic and metastatic breast cancer cell line 
MDA-MB-231 and the chromosome 6-mediated suppressed, non-tumorigenic and 
non-metastatic derivative cell line MDA/H6, resulting in the identification of 651 differentially 
expressed genes. Using customized microarrays containing these 651 cDNAs and 117 con-
trols, we identified 200 frequently dysregulated genes in 10 breast cancer cell lines and 5 
tumor tissues using MDA/H6 as reference. Our bioinformatics analysis revealed that chro-
mosome 6 encodes 25 of these 200 genes, with 4 downregulation and 21 upergulation. 
Northern analysis validated microarray results and was used to detect the size and number of 
RNA species of 2 downregulated (KIAA1949, PTK7) and 2 upregulated (SFRS3, HMGN3) 
genes in the cell lines. Particularly, the KIAA1949 gene at 6p21.33, a band region with the 
frequent cytogenetic aberration and LOH encodes 4 poly(A)-RNA species (4.6-, 4-, 3- and 
1.5-kb) in multiple normal and breast cancer samples. Microarray analysis revealed KIAA1949 
downregulation in 86.7% (n=15) of breast cancer cell lines and tumor tissues. Northern 
analysis demonstrated undetectable and decreased expression of KIAA1949 in 100% (n=10) 
of breast cancer cell lines. Taken together, these results strongly suggest KIAA1949 is a novel 
candidate breast cancer suppressor gene.  
Key words: Breast cancer, MDA-MB-231, Microarray, Tumor suppressor gene, Phostensin, 
KIAA1949 
Introduction 
Cytogenetic and loss of heterozygocity (LOH) 
studies document frequent genetic alterations on 
chromosome 6 in many types of human cancers in-
cluding breast cancer and malignant melanoma. In 
human breast cancer, 18-57% deletion frequencies in 
primary breast tumor tissue (n=72) were reported on 
the short arm of chromosome 6 (6p) using 13 micro-
satellite markers at 6p21 (1). On the long arm of 
chromosome 6 (6q), five distinct regions of allelic im-
balance or LOH were observed in breast cancer tumor Journal of Cancer 2010, 1 
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tissues (2-5) and cell lines (6;7). Functionally, the mi-
crocell-mediated introduction of a neo-tagged chro-
mosome 6 resulted in the suppression of transformed, 
tumorigenic, and/or metastatic characteristics of 
breast cancer cell lines MCF7(8), MDA-MB-231 (8), 
and CAL51 (9), and of the malignant melanoma cell 
line UACC903 (10). The structural and functional 
evidence strongly suggest the presence of chromo-
some 6-encoded tumor suppressor genes that have yet 
to be identified. 
Our study of malignant melanoma using human 
chromosome 6-mediated suppressed melanoma cell 
line UACC903(+6) (10) led to the identification of 
chromosome 6-encoded connexin 43 (Cx43, or gap 
junction protein, alpha 1, 43kDa [GJA1], 6q21-q23.2) 
as a melanoma suppressor gene (11), the transfection 
and overexpression of Cx43 cDNA in breast cancer 
cell line MDA-MB-231 by other investigators sup-
pressed the xenograft tumor growth in athymic nude 
mice (12). Cx43 may be only one of several candidate 
breast cancer suppressor genes encoded by chromo-
some 6. Others include pleiomorphic adenoma 
gene-like 1 (PLAGL1 or Zac1/Lot1, 6q24-q25) (13), 
Parkinson disease (autosomal recessive, juvenile) 2 
(PARK2, 6q25.2-q27) (14), and SAM and SH3 domain 
containing 1 (SASH1, 6q24.3) (15). Because human 
breast cancers are extremely heterogeneous in bio-
logical behavior and clinical outcomes, the pheno-
typic complexity may be due to the broad differences 
in gene expression that are determined by genetic and 
epigenetic alterations accumulated during the cancer 
development and by the gene-environment interac-
tions. In addition, none of above candidate tumor 
suppressor genes can fully explain chromosome 
6-mediated suppression of tumorigenicity in breast 
cancer cell lines MCF7 (8), MDA-MB-231 (8) and 
CAL51 (9). It is conceivable that direct comparison of 
gene expression profile between a breast cancer cell 
line and its chromosome 6-mediated suppressed de-
rivative cell line may lead to the identification of a 
putative breast cancer suppressor gene. 
The DNA microarray technology (16) has facili-
tated the identification of expression profiles and as-
sociation of abnormal patterns to hereditary breast 
cancer (17), sporadic breast cancer (18;19), and clinical 
outcomes (20;21). Combined with PCR subtraction, 
DNA microarrays were also used for rapid isolation 
of differentially expressed genes in breast cancers 
(22;23). Using cDNA microarrays, we had successfully 
identified the chromosome 6-encoded tumor sup-
pressor gene Cx43 (11). In this study, we describe the 
identification of another chromosome 6-encoded 
novel candidate tumor suppressor gene KIAA1949 
(phostensin) using both genome-wide microarrays of 
25,985 cDNA probes and customized microarrays of 
651 genes and 117 controls. The genome-wide micro-
arrays were used to screen differentially expressed 
genes between the tumorigenic and metastatic breast 
cancer cell line MDA-MB-231 and the chromosome 
6-mediated suppressed non-tumorigenic and 
non-metastatic derivative cell line MDA/H6. The 
customized cDNA microarray contained double sets 
of 651 genes and 117 controls per glass slide and was 
used to analyze expression profiles in 10 breast cancer 
cell lines and 5 primary breast tumor specimens with 
MDA/H6 as a reference. Microarray analysis identi-
fied 200 frequently dysregulated genes in these breast 
cancer samples. Out of the 25 genes that are known to 
be encoded by chromosome 6, four were downregu-
lated but 21 were upergulated. Northern analysis va-
lidated the microarray results. The KIAA1949 gene is 
known at 6p21.33, a band region with the frequent 
cytogenetic aberration and LOH. Our Northern anal-
ysis on KIAA1949 detected four poly(A)-RNA bands 
(4.6-, 4-, 3- and 1.5-kb) in multiple normal and breast 
cancer samples. Microarray analysis revealed the 
downregulation of KIAA1949 in 86.7% (n=15) of 
breast cancer cell lines and tumor tissues. Northern 
analysis demonstrated 100% (n=10) downregulation 
in the cell lines. Taken together, these results strongly 
suggest that KIAA1949 is a novel candidate breast 
cancer suppressor gene. 
 
Materials and Methods 
Cell lines, tumor tissues, and cell culture con-
ditions: Table 1 list 11 breast cancer cell lines and 5 
tumor tissues used in this study. Ten breast cancer cell 
lines were purchased from American Type Culture 
Collection (www.atcc.org). The MDA/H6 cell line (8) 
was generously provided by Dr. Negrini. Cells were 
cultured in DMEM medium with L-glutamine sup-
plemented with 10% fetal bovine serum. G418 (800 
μg/ml) was added to MDA/H6 cell culture to select 
for the neo-tagged chromosome 6. 100 U penicillin G 
sodium and 100 µg streptomycin sulfate were added 
into each milliliter of all cell culture media as antibio-
tics. Breast cancer tissue samples with pathological 
reports were purchased from the Lombardi Cancer 
Center Histopathology/Tissue Core, Georgetown 
University Medical Center. The patients’ identifica-
tions of all tissue samples had been removed by the 
core facility personnel before the PI received the 
samples. All media, serum, and antibiotics were ob-
tained from GIBCO BRL (Gaithersburg, MD).  
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Table 1. Human Breast Cancer Cell Lines and Tumor Tissues 
Name Symbol  Original Clinical Diagnosis  Source 
MDA-MB-231 MB231  Adenocarcinoma  ATCC* 
MDA/H6 MDA/H6 Non-tumorigenic  Dr. Negrini (8) 
MDA-MB-134 MB134  Carcinoma  ATCC 
MDA-MB-157 MB157  Carcinoma  ATCC 
MDA-MB-436 MB436  Adenocarcinoma  ATCC 
MDA-MB-453 MB453  Carcinoma  ATCC 
MDA-MB-468 MB468  Adenocarcinoma  ATCC 
BT-20 BT20  Adenocarcinoma  ATCC 
BT-474 BT474  Ductal  carcinoma  ATCC 
BT-549 BT549  Ductal  carcinoma  ATCC 
ZR75-1 ZR751  Ductal  carcinoma  ATCC 
Breast cancer tissue 1  BCTis-1  Poorly differentiated invasive ductal carcinoma  LCC* 
Breast cancer tissue 2  BCTis-2  Poorly differentiated infiltrating ductal carcinoma  LCC 
Breast cancer tissue 3  BCTis-3  Poorly differentiated infiltrating carcinoma  LCC 
Breast cancer tissue 4  BCTis-4  Poorly differentiated infiltrating ductal carcinoma  LCC 
Breast cancer tissue 5  BCTis-5  Poorly differentiated infiltrating ductal carcinoma  LCC 
* ATCC: American Type Culture Collection; LCC: Lombardi Cancer Center Histology Facility.  
 
 
Tumorigenicity test. The test was performed by 
the standard methods in the IACUC approved animal 
protocol and core facility. Briefly, 0.1 ml of 5 x 107 cells 
per ml were inoculated in subcutaneous fat pad at one 
site of flank of female athymic nude mice at age of 4 
weeks. Three mice per cell line were tested. The mice 
were subject to euthanasia when a tumor reaches 20 
mm in diameters. Otherwise, the mice were under the 
standard housing, feeding and observation for 2 
months. After euthanasia, tumors and inoculation 
sites were dissected from the mice for the gross ex-
amination of tumor size and morphology. The distant 
organs (brain, lung, liver, kidney, spleen and bone 
marrow) were collected to culture metastatic human 
breast cancer cells. 
RNA and DNA preparation: Total RNA was 
extracted from cultured cells using Trizol Reagent 
(Invitrogen, Carlsbad, CA, USA) and purified using 
RNeasy kit (Qiagen, Valencia, CA, USA), following 
the commercial instructions. Poly(A)-RNA was ex-
tracted from total RNA samples by use of Dyna-
beads® mRNA Purification Kit (Cat.# 610-06, Invi-
trogen), following the manufacture instructions. Cul-
ture of E. coli strain DH5α, isolation of plasmid DNA 
and PCR amplification of cDNA inserts were de-
scribed previously (24).  
Microarray hybridization on high density gene 
filters of cDNA microarrays: High density gene fil-
ters (gf200, gf201, gf202, gf203 and gf211) were pur-
chased from Research Genetics (Huntsville, AL). New 
gene filters were first washed in boiling 0.5% SDS for 
5 min., placed in a 35 x 150 mm roller tube (052-002, 
Biometra, Tampa) with the DNA side facing the cen-
ter of the tube, and then incubated in 5-mL 
pre-hybridization solution (HYB125.GF, Research 
Genetics) with 5-µl Poly(dA) (POLYA.GF, Research 
Genetics) and 5-µl Cot-1 DNA (15279-011, Life Tech-
nologies) at 42°C for 2 to 4 hours.  
The first strand cDNA was labeled as follows. 
Total RNA (0.8μg) was suspended to 8-μl Rnase-free 
water. Two μl of 1μg/μl 10-20 mer of Oligo-(dT) 
(POLYT.GF, Research Genetics) was added to the 
RNA solution in a tube that was then incubated in a 
65°C for 10 min. Then, 6-μl 5X First Strand Buffer 
(18064-014, Life Technologies), 1-μl of 0.1 M DTT 
(18064-014, Life Technologies), 1.5-μl of 100 mM 
dNTP (27-2035-02, Amersham Pharmacia), 1.5-μl Su-
perscript II reverse transcriptase (18064-014, Life 
Technologies) and 10-μl [α-33P]dCTP (BF1003, Amer-
sham Pharmacia) were added and mixed thoroughly. 
The mixture was placed in a water bath at 37°C for 90 
minutes.  
The labeled cDNA was brought up to 100-μl 
Rnase-free water and then purified by use of a 
Bio-Spin 6 chromatography column (732-6002, 
Bio-Rad, Hercules, CA) following the manufacturer's 
instruction. DNA with more than 5% of α-33P incor-
poration, measured by use of Scanner QC4000 (Bios-
can Inc. Washington, D.C.), was denatured for 5 min 
in a boiling water bath and added directly to the 
pre-hybridization. The hybridization was allowed to 
continue for 15 h at 42°C. The washes were done to 
the final stringency of 0.5x SSC, 1% SDS at 50oC for 15 
min. The filters were placed on ddH2O-moistened 
piece of Whatmann paper (28458-005, VWR, Bridge-
port, NJ), exposed onto a phosphor screen (Molecular 
Dynamics) for 5 h, and scanned for signals with the 
Storm 840 Scanner (Molecular Dynamics). The tiff 
images were transferred to software IP-
Lab/ArraySuite v2.0 (NHGRI/NIH) for identification Journal of Cancer 2010, 1 
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of differentially expressed genes as described pre-
viously(11).  
Customized microarrays on glass slides: Me-
thods for making DNA microarrays on glass slides 
were described previously (24). Briefly, human cDNA 
inserts were amplified by PCR using the vector se-
quence-specific primers flanking the inserts on plas-
mid DNA. The purified DNA (0.2 μg/ml) of 651 
cDNAs, 80 housekeeping genes for ratio control (25), 4 
non-specific DNA controls and 33 negative controls 
were printed in double sets on poly(Lysine)-coated 
glass slides. 
The first strand cDNA was labeled by using Mi-
croMax Kit 501 (NEN, Boston, MA) following the 
manufacturer's instruction. All cancer samples were 
labeled with the fluorescent Cy3-dUTP and the ref-
erence sample (MDA/H6) with Cy5-dUTP. Briefly, 
50-μg total RNA was mixed with Cy3-dUTP (or 
Cy5-dUTP) and other reagents from the kit to syn-
thesize the label first strand cDNA at 42°C for 1 h. The 
reaction was stopped by addition of 2.5-μl 0.5M EDTA 
and 2.5-μl 1N NaOH and then incubated at 65°C for 
30 min. After adding 6.2-μl 1M Tris-HCl (pH 7.5), the 
samples were purified by use of Microcon 100 (Cat. 
No. 42412, Millipore Corp., Bedford, MA) to remove 
unincorporated nucleotides and salts. The Cy3- and 
Cy5- labeled DNA samples of each pair were dis-
solved into 25-μl Hybridization Buffer from the kit by 
heating at 50°C for 10 min prior to placing onto a mi-
croarray slide. Hybridization was allowed to proceed 
at 65°C for 16 h. The slides were washed to a final 
stringency of 0.06 x SSC at room temperature for 15 
min. Slides were scanned by use of GenePix 4000A 
Laser Scanner (Axon Instruments, Inc., Foster City, 
CA). For each slide, two fluorescent intensities (Cy3, 
Cy5) were scanned separately and then placed into 
the red and green channel as the tiff images in soft-
ware IPLab/ArraySuite v2.0 (NHGRI, NIH) for anal-
ysis as described previously (25). 
Database and bioinformatics data analysis: 
Gene expression database, data filtering and selection 
were constructed and performed as described pre-
viously (26). The quantile normalization method (27) 
in software R version 2.7.1 (The R Foundation for Sta-
tistical Computing) was used to normalize microarray 
data. Hierarchical dendrogram clustering analysis of 
genes and samples were carried out by using software 
Cluster version 3.0 (28) and heatmap was visualized 
by using software MapleTree (http://rana.lbl.gov/ 
EisenSoftware.htm). Gene ID, symbols and names 
were updated to human UniGene Build 221 
(ftp://ftp.ncbi.nih.gov/repository/UniGene) based 
on human cDNA IMAGE clone ID 
(http://image.llnl.gov). Ontology, pathways and 
phenotypes of genes were compiled from Entrez 
(ftp://ftp.ncbi.nlm.nih.gov/gene) and DAVID Bio-
informatics Resources 2008 (http://david.abcc. 
ncifcrf.gov). The mapped details of all chromosome 
6-encoded genes were based on Homo sapiens Map 
Viewer Build 37.1 (www.ncbi.nlm.nih.gov/ 
mapview).  
Northern analysis: Northern hybridization was 
performed by standard methods (29). Total RNA or 
poly(A)-RNA, 20 μg per lane, was fractionated in 1.2% 
agarose-formaldehyde gels by electrophoresis. RNA 
was transferred onto Hybond-N+ membranes 
(Amershan Life Science) by capillary blotting over-
night. The cDNA sequences of IMAGE Consortium 
EST clones: 208699 (KIAA1949), 813742 (PTK7), 173554 
(SFRS3), 781404 (HMGN3), and 759200 (DHPS) were 
determined by DNA sequence analysis. Particularly, 
the cDNA fragments of 208699 correspond to the 
KIAA1949 full length mRNA sequence from 3827 to 
4598 (www.ncbi.nlm.nih.gov/nuccore). The cDNA 
fragments of probe DNA were amplified by polyme-
rase chain reaction (PCR) using vector-specific pri-
mers as described previously (24). The probes were 
labeled with [α-32P]dCTP using a Random Primed 
DNA Labeling Kit (Roche Applied Science, Indianap-
olis, IN). Northern hybridization was performed at 
65oC for 16 hours in 5 ml hybridization solution in-
cluding the final concentrations of 5 x SSC, 5 x Den-
hardt’s solution, 1.5% (w/v) SDS, 0.5 μg/ml of dena-
tured salmen sperm DNA and 25 ng of 
[α-32P]dCTP-labeled probe. The membrane were 
washed in 0.1 x SSC at 42oC for 20 min. Blots were 
exposed to Kodak X-Omat AR film at -80oC for 16 
hours to 3 days. 
Results 
Strategy, validation of tumorigenicity, and 
screening differentially expressed genes. Figure 1 
diagrammatically illustrates our strategy for the iden-
tification of a breast cancer tumor suppressor gene 
encoded by chromosome 6. First, we performed a 
tumorigenicity test to confirm phenotypic features of 
the breast cancer cell lines MDA-MB-231 and 
MDA/H6. MDA-MB-231 is a tumorigenic and me-
tastatic breast cancer cell line. The introduction of a 
neo-tagged human chromosome 6 into MDA-MB-231 
by Negrini et. al. generated the non-tumorigenic de-
rivative cell line MDA/H6 (8). The results of our tu-
morigenicity test showed that the MDA-MB-231 cell 
line formed xenograft tumors rapidly (visible in three 
days and reaching more than 1 cm in diameter in two 
weeks) after inoculation in subcutaneous fat pad of 
the mice. Moreover, the culture of the mouse organs 
(brain, lung, liver, spleen, kidney and bone marrow) Journal of Cancer 2010, 1 
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distant from the primary xenograft tumor sites re-
v e a l e d  g r o w t h  o f  m e t a s t a t i c  M D A - M B - 2 3 1  c e l l s .  I n  
contrast, the MDA/H6 cell line did not give either 
visible tumor or metastatic cancer cells after the pa-
rallel inoculation for two months (Fig. 1). Secondly, 
we screened 25,985 cDNA probes for differentially 
expressed genes by microarray analysis of gene ex-
pression profile between these two cell lines. Using 
the threshold of more than 800 signal intensities and 
more than 2-fold expression differences, we identified 
651 (2.5%) genes as the differentially expressed genes. 
Thirdly, we designed and fabricated customized mi-
croarrays with 651 genes and 117 various controls on 
glass slides to identify frequently dysregulated genes 
in multiple breast cancer cell lines and tumor tissues 
in comparison to MDA/H6. Fourthly, by correlating 
frequently downregulated genes to the chromosome 
band regions with known cytogenetic aberration and 
LOH, we identified a novel candidate tumor sup-
pressor gene for further analysis.  
High quality customized microarrays. Using 
the resultant 651 differentially expressed genes 
and 117 control probes, we designed and 
printed cDNA microarrays with these 768 
DNAs in duplicate on each poly(lysine)-coated 
glass slide. The same batch of microarrays was 
used to measure gene expression in all breast 
cancer cell lines and tumor tissues studied. 
Figure 2A and 2B show the representative mi-
croarray images derived from hybridization 
with Cy3- and Cy5-labeled cDNA of the 
MDA-MD-231 and MDA/H6 cells. The cali-
brated expression ratios of informative genes 
(>800 average intensities in either red or green chan-
nel) from these two cell lines were subjected to 
log-transformation to obtain approximate normal 
distribution. The log-transformed ratios from one set 
of genes were drawn against those from the other as a 
scatter plot, from which a linear regression and Pear-
son coefficient of correlation were computed. Figure 
2C and 2D show the strong positive linear relations 
(y=0.9944x + 0.0305 and y=0.9909x + 0.0079) between 
Set A and Set B on Slide 1 and Slide 2, respectively. In 
addition, Pearson coefficient of correlation between 
Set A and Set B on Slide 1 and Slide 2 were 0.9857 and 
0.9744, respectively. The expression ratios of genes 
from Set A and Set B were averaged for the same 
slides. The resultant values from Slide 1 were plotted 
against those from Slide 2. The results indicated, as 
expected, a strong positive linear relation (y=1.0033x 
+ 0.0058) with a high Pearson coefficient of correlation 
(r = 0.9823) (Fig. 2E). These results demonstrated the 
strength of reproducibility of the customized gene 
chips and microarray experiments.  
 
 
 
 
Fig. 1. Experimental strategy and tumorige-
nicity. (A) A flow diagram illustrates the experi-
mental strategy. (B) Human breast cancer cell line 
MDA-MB-231 formed tumor in athymic nude mice 
after s.c. inoculation of 5 x 10
6 cells in athymic nude 
mice for 2 weeks. (C) MDA/H6 is a MDA-MB-231 
derivative cell line that contains a neo-tagged human 
chromosome 6 and did not form any tumor after the 
inoculation for 2 months. DEG: differentially ex-
pressed gene; TSG: tumor suppressor gene. 
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Fig. 2. High quality customized cDNA microarray. (A, B) The images of two sets of 768 genes on the same glass 
slide. The image A shows the identical patterns with the image B. The enlarged image parts at i, ii, and iii in the set (A) are 
identical to those at i’, ii’ and iii’ in the set (B). (C, D) Statistical analysis of the expression ratios of 200 informative genes 
between MDA-MB-231 and MDA/H6 were detected by two sets of genes (images A and B) on Slide 1 (C) and on Slide 2 (D). 
(E) The average ratios of the gene expression from Slide 1A and 1B were plotted against the average ratios from Slide 2A 
and 2B. The linear regression and Pearson coefficient of correlation were computed from the scatter plots that are on 
log-scale. The strong linear relations and high values of Pearson coefficient of correlation (r) are indicated in each com-
parison. "x": an gene expression ratio between MDA-MB-231 and MDA/H6 on x-axis; "y": the ratio between these two 
samples on the y-axis corresponding to a given "x". 
Gene expression profiles of breast cancer cell 
lines and tumor tissues. The customized cDNA mi-
croarrays of the same batch were used to measure 
expression of 768 probes in duplicate in 11 breast 
cancers cell lines (MDA-MB-231, MDA/H6, 
MDA-MB-134, MDA-MB-157, MDA-MB-436, 
MDA-MB-453, MDA-MB-468, BT-20, BT-474, BT-549 
and ZR75-1), and 5 breast cancer tumor tissue samples 
1-5 (Table 1). To ensure consistent measures between 
Cy3- and Cy5-dUTP labeling, the fluorescence dye 
sways were performed on the MDA-MB-231 and 
MDA/H6 RNA samples, each in triplicate, and thus, a 
total of 6 microarray comparisons were performed. 
Then, RNA samples of MDA/H6 were labeled with 
Cy5-dUTP as the reference while other samples were 
labeled with Cy3-dUTP as the tests for microarray 
comparisons. Taken together, a total of 20 microarray 
experiments were performed and resultant 40 micro-
array images were processed for database construc-
tion and microarray data analysis. Out of 768 unique 
elements arrayed, 200 (26.04%) passed a uniform cri-
teria that the average intensities of a spot in red or 
green channel was greater than 2,000 in the range 
from 0 to 65,535 and significantly differentially ex-
pressed in the breast cancers studied. The ratios of 
these 200 genes between a test sample and the refer-Journal of Cancer 2010, 1 
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ence RNA were used for unsupervised hierarchical 
clustering analysis. The results showed that all six 
comparisons of MDA-MB-231 with MDA/H6 were 
grouped in the same cluster as expected, with five 
breast cancer tumor samples in another group, and 9 
breast cancer cell lines between the other two groups. 
The heatmap revealed 4 groups of genes, Group A 
with downregulation in all samples, Group B with 
downregulation in MDA-MB-231 and upregulation in 
others, Group C with upregulation in all samples, and 
Group D with upregulation in MDA-MB-231 and 
downregulation in others. (Fig. 3) 
Chromosome 6-encoded differential-
ly-expressed genes. Our bioinformatics analysis po-
sitioned all 200 differentially expressed genes onto 
their known chromosome band regions based on 
Homo sapiens Map Viewer Build 37.1. Figure 4 and 
Table 2 show the chromosome 6-encoded 25 genes 
and their expression levels in 10 breast cancer cell 
lines and 5 tumor tissues relative to those in 
MDA/H6. The chromosome 6 band regions with 
known cytegenetic aberration and LOH were also 
indicated in Figure 4. Thirteen genes were mapped to 
the short arm of chromosome 6 and 12 on the long 
arm, including in the order from the short arm to the 
long arm: NAD(P)H dehydrogenase quinone 2 
(NQO2, 6p25.2), human immunodeficiency virus type 
I enhancer-binding protein 1 (HIVEP1, 6p24.1), ade-
nylyl cyclase-associated protein 2 (CAP2,  6p22.3), 
SOX4 (6p22.3), zinc finger protein 184 (ZNF184, 
6p22.1), transcribed locus-b (6p21.33), KIAA1949 
(6p21.33), tubulin beta (TUBB, 6p21.33), ribosomal 
protein L10a (RPL10A, 6p21.31), splicing factor argi-
nine/serine-rich 3  (SFRS3, 6p21.31), testis devel-
opment related protein 1 (TDRG1, 6p21.2), protein 
tyrosine kinase 7 (PTK7, 6p21.1), transcribed locus-a 
(6p21.1), collagen type XII alpha 1 (COL12A1, 6q13), 
high mobility group nucleosomal binding domain 3 
(HMGN3, 6q14.1), transcribed locus-c (6q14.1), CD164 
antigen sialomucin (CD164, 6q21), phospholamban 
(PLN, 6q22.1), serum/glucocorticoid regulated kinase 
(SGK1, 6q23), splicing factor 3b subunit 5 10kDa 
(SF3B5, 6q24.2), chromosome 6 open reading frame 
211 (C6orf211, 6q25.1), T-cell lymphoma invasion and 
metastasis 2 (TIAM2, 6q25.2), acetyl-Coenzyme A 
acetyltransferase 2 (ACAT2, 6q25.3), ribosomal pro-
tein S6 kinase 90kDa polypeptide 2 (RPS6KA2, 6q27), 
and programmed cell death 2  (PDCD2,  6q27).  Out 
of these 25 genes, NQO2 and KIAA1949 were down-
regulated in 15 and 13 breast cancer samples, respec-
tively. Both TUBB and SF3B5 were downregulated in 
8 tumor samples and upregulated in one. PTK7 was 
downregulated in 6 samples and upregulated in 7. 
The other genes were essentially upregulated at a 
high frequency in these 15 breast cancer cell lines and 
tumor tissues. Both KIAA1949 and TUBB are encoded 
in 6p21.33, a band region with the known high fre-
quency in LOH. (Fig. 4 and Table 2)  
Table 2. Expression Ratios of 25 Chromosome 6-Encoded Genes in Breast Cancer Cell Lines (n=10) and Tumor Tissues 
(n=5) to the MDA/H6 Cell Line. 
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6p25.2 NQO2 0.74 0.26 0.06 0.05 0.07 0.06 0.15 0.06 0.14 0.03 0.78 0.13 0.63 0.09 0.04
6p24.1 HIVEP1 1.58 2.96 1.32 1.57 1.64 1.42 1.13 1.86 1.98 1.78 39.27 2.83 3.03 1.92 2.17
6p22.3 CAP2 0.84 1.11 2.23 1.05 1.33 1.53 0.70 1.70 1.34 1.82 1.05 0.67 1.09 11.41 0.68
6p22.3 SOX4 1.12 8.35 8.45 3.78 4.89 4.48 1.10 3.78 1.88 9.42 4.53 3.87 28.86 6.58 40.59
6p22.1 ZNF184 0.82 1.62 1.73 2.44 2.08 1.43 0.82 1.67 1.34 1.41 5.77 1.60 3.56 1.43 1.11
6p21.33 EST-b 1.01 3.11 1.60 2.61 3.55 3.47 2.22 1.88 2.20 3.00 6.51 7.06 1.97 3.66 2.28
6p21.33 KIAA1949 0.35 0.32 0.11 0.48 0.11 1.04 0.35 0.10 0.11 0.16 1.14 0.24 0.73 0.06 0.03
6p21.33 TUBB 0.90 1.04 0.99 0.94 0.49 0.58 0.48 0.31 0.59 0.87 1.35 0.51 0.94 0.31 0.21
6p21.31 RPL10A 0.86 1.18 1.09 1.66 0.82 1.51 1.01 0.68 1.01 1.19 5.77 0.90 2.06 0.87 1.06
6p21.31 SFRS3 2.46 1.76 2.10 1.33 1.51 1.79 1.33 1.40 1.63 2.59 3.23 1.26 2.37 7.35 8.03
6p21.2 TDRG1 1.39 1.77 1.59 1.08 2.00 1.43 1.84 0.83 1.53 1.53 4.35 3.13 3.94 8.04 1.26
6p21.1 PTK7 0.64 1.89 0.63 1.87 0.86 1.90 0.37 0.54 2.02 1.14 4.81 0.78 3.01 1.20 0.42
6p21.1 EST-a 1.42 4.68 3.67 3.99 3.50 6.95 2.44 1.94 2.89 2.38 6.51 1.66 1.97 0.35 0.39
6q13 COL12A1 1.28 1.13 1.36 4.56 1.09 2.27 0.89 1.24 3.21 4.52 4.60 3.40 9.25 3.19 6.80
6q14.1 HMGN3 1.19 2.38 1.40 0.80 2.52 1.94 1.83 1.37 0.52 2.93 2.81 1.44 1.43 10.01 4.70
6q14.1 EST-c 1.02 3.75 3.16 4.25 4.18 9.82 2.63 2.86 2.43 2.41 6.51 1.66 2.82 0.35 0.39
6q21 CD164 1.70 4.03 1.21 1.66 0.65 1.43 2.24 0.84 1.73 3.81 3.24 0.96 5.09 5.07 6.86
6q22.1 PLN 1.02 5.61 2.67 3.78 4.71 10.27 2.63 2.11 3.19 4.03 27.85 9.48 4.67 1.68
6q23 SGK1 0.93 2.93 1.41 1.85 1.57 1.04 2.87 1.49 1.64 1.81 6.51 1.66 1.44 2.67 0.88
6q24.2 SF3B5 0.96 0.51 0.80 0.73 0.76 0.96 0.89 0.58 0.46 0.52 1.78 1.12 0.85 0.41 1.20
6q25.1 C6orf211 1.21 0.68 4.11 1.07 2.06 0.99 0.79 1.00 1.31 4.28 1.66 2.00 1.13 42.75 18.16
6q25.2 TIAM2 0.98 3.83 0.64 2.21 1.86 2.88 1.77 1.67 0.88 1.13 6.51 3.33 2.06 6.17 3.30
6q25.3 ACAT2 1.07 1.78 1.25 1.78 2.00 0.77 0.95 1.10 1.05 1.39 3.98 2.83 0.75 2.16 0.73
6q27 RPS6KA2 2.81 4.06 1.80 2.60 2.07 1.36 1.75 2.30 1.03 1.57 6.51 7.36 0.69 0.35 2.99
6q27 PDCD2 0.80 3.16 1.57 1.64 2.17 1.53 1.62 1.16 1.07 2.03 16.63 3.17 2.62 0.20 0.36Journal of Cancer 2010, 1 
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Fig. 3. Cluster and heat 
map  of 200 differentially 
expressed genes in 10 
breast cancer cell lines and 
5 cases of breast cancer 
tumor tissues compared 
with the MDA/H6 cell line 
based on 20 microarray 
experiments and 40 mi-
croarray images. (a) A 
cluster of genes downre-
gulated in most samples, (b) 
downregulated in 
MDA-MB-231 but upregu-
lated in most other sam-
ples, (c) upregulated in 
almost all samples, and (d) 
upregulated in 
MDA-MB-231 but down-
regulated in most other 
samples. The color bar 
indicates color map and fold 
changes in expression ra-
tios. 
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Fig. 4. Expression patterns of 25 chromosome 6-encoded genes in 10 breast cancer cell lines and 5 cases of breast 
cancer tumor tissues compared with the chromosome 6-mediated suppressed non-tumorigenic and non-metastatic breast 
cancer cell line MDA/H6. The gene expression ratio between MDA-MB-231 and MDA/H6 were derived from 12 microarray 
images with Cy3 and Cy5 dye sways in cDNA labeling, while the ratio between others and MDA/H6 were from the duplicate 
microarrays. Cytobands indicate chromosome 6 band regions of the resultant genes. The color map indicates fold changes 
in expression ratios. LOH: loss of heterozygosity was based on the compiled data from the PUBMED literature. Yellow 
color indicates the highest frequency in LOH documented in literature; EBP: enhancer-binding protein. 
 
Validation of RNA expression and detection of 
RNA sizes by Northern blots. To validate microarray 
results, we conducted Northern analyses of RNA le-
vels for KIAA1949, PTK7, SFRS3, HMGN3 in 11 breast 
cancer cell lines, using deoxyhypusine synthase 
(DHPS, 19p13.13) as control for RNA loading and 
transfer because of its relative consistent RNA levels 
in these 11 breast cancer cell lines revealed by the mi-
croarrays. Twenty micrograms of total RNA per lane 
from each cell line were used for Northern blots. The 
results demonstrated the presence of two transcripts 
(4 kb and 3 kb) of KIAA1949 in 8 of 11 cell lines. In 
comparison to MDA/H6, the KIAA1949 RNA levels 
were absent in ZR75-1 and BT-474, had 2-20 fold 
downregulation in MDA-MB-231, MDA-MB-463, 
MDA-MB-453, MDA-MB-468, BT-20, MDA-MB-157 
and MDA-MB-134, but displayed no change in 
BT-549. Four of other genes (PTK7, SFRS3, HMGN3 
and DHPS) each had only one transcript. The RNA 
levels of PTK7 were downregulated in MDA-MB-231, 
ZR75-1 and MDA-MB-436, no change in 
MDA-MB-134, but upregualted in BT-474, BT-549, 
MDA-MB-453, MDA-MB-468, BT-20 and 
MDA-MB-157. The SFRS3 RNA was upregulated in 
all 11 breast cancer cell lines. The HMGN3 RNA had 
no change in MDA-MB-231 and BT-20, but showed 
upregulation in others. (Fig. 5) 
Detection of 4 poly(A)-RNA variants of 
KIAA1949 and their downregulation in breast can-
cer cell lines. Our Northern analysis using total RNA 
detected 2 RNA species of KIAA1949 in multiple 
breast cancer cell lines. To see the RNA sizes and 
changes in expression, we performed Northern anal-
ysis using 20 μg of poly(A)-RNA per lane from each of 
11 breast cancer cell lines. The results demonstrated 
the presence of 4 mRNA species of KIAA1949 gene, 
including 4.6-, 4-, 3- and 1.5-kb. In comparison to 
MDA/H6, these mRNA species were either unde-
tectable or downregulated in all 10 breast cancer cell 
lines tested. Specifically, these RNA bands were ab-
sent in ZR75-1, BT474 and BT20, barely detectable in 
MDA-MB-453, MDA-MB-468 and MDA-MB-134, and 
significantly decreased in MDA-MB-231, 
MDA-MB-436 and MDA-MB-157. In the case of 
BT-549 cell line, 4.6kb band displayed more than 
5-fold decrease but 3kb band showed an approx-
imately 3-fold increase. (Fig. 6A)  Journal of Cancer 2010, 1 
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Fig. 5. (A) Northern hybridization blots show the RNA levels of 4 genes in 10 breast cancer cell lines (1-10) in 
comparison to MDA/H6. 20 micrograms of RNA were loaded in each lane. 208699: KIAA1949; PTK7: protein tyrosine 
kinase 7; SFRS3: splicing factor arginine/serine-rich 3; HMGN3: high mobility group nucleosomal binding domain 3; DHPS: 
deoxyhypusine synthase as a control for RNA loading and transfer. (B) Bar graph of relative RNA levels detected by 
microarray and Northern experiments. Both sets of data were first normalized to DHPS and MDA/H6, and then compared 
as the bar graph. The arrowheads indicate 4 differences. Thus, 90% (40 comparisons) expression changes were consistent 
between these two independent experiments. 1, MDA-MB-231; 2, ZR75-1; 3, BT474; 4, MDA-MB-436; 5, BT549; 6, 
MDA-MB-453; 7, MDA-MB-468; 8, BT-20; 9, MDA-MB-157; and 10, MDA-MB-134. 
 
Fig. 6. Northern hybridiza-
tion blots show 4 
poly(A)-RNA bands (4.6-, 4-, 3- 
and 1.5-kb) and levels of 
KIAA1949 detected by 208699 
probes in 10 breast cancer cell 
lines (1-10) in comparison to 
MDA/H6. (A) Northern blots 
of poly(A)-RNA for 11 breast 
cancer cell lines with 20 mi-
crograms of poly(A)-RNA per 
lane. (B) Northern blots of the 
Clontech Northern membrane 
with poly(A)-RNA from human 
normal tissues, Ske Mus, ske-
letal muscle; Sma Int, small 
intestine; Pe Bl Le, peripheral 
blood leukocyte. (C) Northern 
blots of 20 micrograms of total 
RNA. DHPS: deoxyhypusine 
synthase and ACTB: beta actin, 
as controls for RNA loading 
and transfer. 
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To determine whether these 4 transcripts are also 
present in normal tissues, we conducted Northern 
analysis using the Clontech Northern membrane with 
multiple normal tissue poly(A)-RNA. The results 
confirmed the presence of these four transcripts in 13 
normal tissues including heart, placenta, lung, liver, 
skeletal muscle, kidney, pancreas, spleen, thymus, 
prostate, ovary, small intestine and peripheral blood 
leukocyte. These transcripts were very faint in testis 
and colon mucosal lining tissues and were not visible 
in brain tissue. (Fig. 6B) In addition, our Northern 
hybridization with total RNA of human normal 
mammary gland and spleen tissues revealed 
high-level expression of the KIAA1949 bands (or 
smear) in the normal breast tissue. (Fig. 6C)  
Discussion 
Breast cancer is extensively heterogeneous ma-
lignant disease. Identification of expression profiles of 
multiple cancer samples may reveal gene expression 
changes that are specific to individual samples and 
common to most, if not all, samples studied. The 
common expression patterns might represent a 
common “passage” through which the cells evolve 
from one stage to another. Although the high 
throughput technology DNA microarray is very use-
ful to reveal genome-wide gene expression profiles, 
customized microarrays with a focused group of 
genes facilitate a hypothesis-driven study and simpl-
ify microarray data analysis as exemplified by the 
previous study (26). In this study, we combined ge-
nome-wide gene chips with customized microarrays 
to identify chromosome 6-encoded differentially ex-
pressed genes in 10 breast cancer cell lines and 5 tu-
mor tissues in comparison to the chromosome 
6-medidated suppressed non-tumorigenic and 
non-metastatic breast cancer cell line MDA/H6. Spe-
cifically, after screening 25,985 cDNA probes using 
genomic microarrays, we identified 651 genes with 
more than 800 signal intensities and more than 2-fold 
changes in expression between the parental tumori-
genic and metastatic breast cancer cell line 
MDA-MB-231 and the chromosome 6-mediated sup-
pressed non-tumorigenic and non-metastatic deriva-
tive cell line MDA/H6. Then, we designed and fabri-
cated 651 genes with 117 various controls in double 
sets on the individual glass slides. Using the custo-
mized DNA microarrays, we identified 200 frequently 
dysregulated in breast cancer cell lines (n=10) and 
tumor tissues (n=5) in comparison to MDA/H6. Upon 
mapping these genes to chromosome band regions, 
we identified 25 differentially expressed genes that 
are known to be encoded by chromosome 6, of which 
4 genes (KIAA1949, TUBB, NQO2 and SF3B5) were 
downregulated in 50%-100% (n=15) of breast cancer 
samples studied. The KIAA1949 gene with 86.7% 
downregulation in all 15 breast cancers studied is 
located at the chromosome 6 band region with the 
high frequency of LOH. Therefore, we further ana-
lyzed the transcripts and expression levels of 
KIAA1949 in 11 breast cancer cell lines and 17 human 
normal tissues. 
Microarray detection of gene expression can be 
affected by many factors including cell culture condi-
tions, RNA purification, cDNA labeling methods and 
quality of microarrays. In this study, we manufac-
tured high quality microarrays to reduce variance that 
could otherwise be introduced by different gene 
chips. By testing gene expression between 
MDA-MB-231 and MDA/H6 cells in triplicate micro-
array experiments with fluorescent dye sways, we 
demonstrated the strong positive linear relations and 
high values of Pearson coefficient of correlation be-
tween the customized microarrays, and therefore, the 
consistency and reproducibility of the customized 
gene chips and microarray experiments. 
Our combined genome-wide and focused cDNA 
microarray approaches led to the identification of 25 
chromosome 6-encoded genes that were frequently 
dysregulated in 10 breast cancer cell lines and 5 breast 
cancer tumor tissues in comparison to the chromo-
some 6-mediated suppressed non-tumorigenic and 
non-metastatic cell line MDA/H6. Interestingly, only 
KIAA1949 was downregulated frequently in these 
breast cancers and is known to be encoded at 6p21.33, 
a chromosome 6 band region with the PUBMED do-
cumented high frequency in the loss of heterozygosi-
ty. Other genes downregulated in MDA-MB-231 in-
clude CAP2, ZNF184, RPL10A, PTK7 and PDCD2; 
however, they were not frequently downregulated in 
other breast cancer cell lines and tumor tissues. 
NQO2, TUBB and SF3B5 were downregulated rela-
tively frequently in these breast cancers but they were 
not in MDA-MD-231, the parental cell line of 
MDA/H6. All other genes were significantly upre-
gulated in these breast cancers. Therefore, KIAA1949 
is the only strong candidate as a novel breast cancer 
tumor suppressor gene. 
KIAA1949 was originally cloned from a fetal 
brain cDNA library by Nagase et al. who also re-
ported its expression in multiple normal human tis-
sues including spleen, lung, liver, ovary, and other 
adult and fetal tissues (30). Recently, Kao et al. cloned 
KIAA1949 using yeast 2-hybrid screening of a heart 
cDNA library and named it as phostensin based on its 
protein function (31). Kao and colleagues also de-
tected 1.5- and 4.2-kb transcripts in multiple tissues 
except brain, prostate and colon. In our study, the Journal of Cancer 2010, 1 
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RNA expression was detected in the prostate and co-
lon but not in the brain. In addition, we showed a high 
level of RNA in normal human breast tissue. Moreo-
ver, we detected a total of four mRNA species (4.6-, 4-, 
3- and 1.5-kb bands) in 14 of 17 normal tissues and 5 of 
11 breast cancer cell lines studied. A significance of 
the presence of 4 different transcripts for the 
KIAA1949 genes in cells remains to be determined. 
Kao et al named the KIAA1949-encoded 26-kDa 
protein as phostensin based on their discovery of it as 
a regulatory subunit that targets protein phospha-
tase-1 to F-actin cytoskeleton (31). Although Nagase et 
al originally predicted an open reading frame with 
662 amino acid residues for the KIAA1949 protein 
(30), Kao and his colleagues could detect only a 
26-kDa protein (31). This raises the question as to 
whether the 4 transcripts we detected in tissues and 
cells may play a regulatory role for protein synthesis. 
Recently, Lai et al characterized the biochemical func-
tions of phostensin and showed that phostensin de-
creases the elongation and depolymerization rates of 
acting filament pointed ends. Their results suggested 
that phostensin is an actin filament pointed 
end-capping protein that is capable of modulating 
actin dynamics (32), whether this activity has effects 
on cancer cell invasion and metastasis is an interesting 
hypothesis under investigation. 
Our microarray analysis revealed 90% downre-
gulation of KIAA1949 in breast cancer cell lines (n=10) 
and 80% downregulation in the clinically-derived 
breast cancer tumor tissues (n=5). Our Northern 
analysis of the KIAA1949 poly(A)-RNA demonstrated 
100% downregulation in these 10 cell lines including 
30% undetectable, 30% barely detectable and 40% 
significant decrease. Taken all data together, our re-
sults strongly suggest that KIAA1949 is a novel can-
didate breast cancer suppressor gene. In this regard, 
whether phstensin acitivities in modulating actin dy-
namics play any role in cancer cell invasion and me-
tastasis is an interesting hypothesis that merits inves-
tigation. Our tumorigenicity test of breast cancer cell 
lines with and without transfection and overexpres-
sion of phostensin is in progress. 
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